Segment Disclosures - Schedule of Significant Expense (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Operating expenses: | ||||||
| Non-cash stock compensation | $ 11,248 | $ 3,941 | ||||
| Total operating expenses | $ 35,327 | $ 27,083 | 68,562 | 53,908 | ||
| Loss from operations | (35,327) | (27,083) | (68,562) | (53,908) | ||
| Interest income | 1,286 | 241 | 2,046 | 424 | ||
| Other income (expense) | (58) | 22 | (171) | 1,191 | ||
| Net loss | (34,099) | $ (32,588) | (26,820) | $ (25,473) | (66,687) | (52,293) |
| Reportable Segment | ||||||
| Operating expenses: | ||||||
| Clinical product candidates | 17,433 | 17,710 | 38,354 | 35,491 | ||
| Pre-clinical product candidates | 504 | 231 | 923 | 345 | ||
| Non-cash stock compensation | 6,782 | 1,899 | 11,248 | 3,941 | ||
| Depreciation expense | 34 | 43 | 67 | 86 | ||
| Professional fees and other segment expenses | 4,309 | 2,523 | 7,338 | 5,641 | ||
| Total operating expenses | 35,327 | 27,083 | 68,562 | 53,908 | ||
| Loss from operations | (35,327) | (27,083) | (68,562) | (53,908) | ||
| Interest income | 1,286 | 241 | 2,046 | 424 | ||
| Other income (expense) | (58) | 22 | (171) | 1,191 | ||
| Net loss | (34,099) | (26,820) | (66,687) | (52,293) | ||
| Reportable Segment | Income Statement Location [Axis]: us-gaap:GeneralAndAdministrativeExpense | ||||||
| Operating expenses: | ||||||
| Employee costs | 2,451 | 2,083 | 4,260 | 3,643 | ||
| Reportable Segment | Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpense | ||||||
| Operating expenses: | ||||||
| Employee costs | $ 3,814 | $ 2,594 | $ 6,372 | $ 4,761 | ||
| X | ||||||||||
- Definition The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of noncash expense for share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Clinical Product Candidates No definition available.
|
| X | ||||||||||
- Definition Pre Clinical Product Candidates No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|